49 Papers
41 Citations
Bin Meng is an academic researcher from Tianjin Medical University Cancer Institute and Hospital. The author has contributed to research in topics: Medicine & Diffuse large B-cell lymphoma. The author has an hindex of 10, co-authored 34 publications. Previous affiliations of Bin Meng include Tianjin Medical University & University of Nebraska Medical Center.
Chat about Author
Papers
Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma
Weicheng Ren,Xiaofei Ye,Hong Su,Wei Li,Wei Li,Dongbing Liu,Mohammad Pirmoradian,Xianhuo Wang,Bo Zhang,Qiang Zhang,Longyun Chen,Man Nie,Man Nie,Yao Liu,Bin Meng,Huiqiang Huang,Wenqi Jiang,Yi Xin Zeng,Wenyu Li,Kui Wu,Yong Hou,Klas G. Wiman,Zhi Ming Li,Huilai Zhang,Roujun Peng,Shida Zhu,Qiang Pan-Hammarström,Qiang Pan-Hammarström,Qiang Pan-Hammarström +28 more
TL;DR: It is shown that patients with concomitant HBV infection (surface antigen positive [HBsAg+]) are characterized by a younger age, a more advanced disease stage at diagnosis, and reduced overall survival, the first comprehensive genomic and transcriptomic study that suggests a link betweenHBV infection and B-cell malignancy.
115
Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China
Qianru Guo,Ning Liu,Frank Wang,Yuhong Guo,Bo Yang,Zi Cao,Yalei Wang,Yong Wang,Wenshuai Zhang,Qiujuan Huang,Wei Zhao,Changxu Liu,Tongyuan Qu,Lingmei Li,Lu Cao,Danyang Ren,Bin Meng,Lisha Qi,Cheng Wang,Wenfeng Cao +19 more
TL;DR: A group of low-grade oncocytic renal tumors identified retrospectively in a large tertiary cancer center, which was probably the first report originated from China or even Asia in the English literature so far, is described.
48
Pembrolizumab Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Oesophageal Squamous Cell Carcinoma: Protocol for a Multicentre, Prospective, Randomized-Controlled, Phase III Clinical Study (Keystone-002)
Xiaobin Shang,Wencheng Zhang,Gang Zhao,Fei Liang,Chen Zhang,Jie Yue,Xiaofeng Duan,Zhao Ma,Chuang Chen,Qingsong Pang,Weihong Zhang,Liang Liu,Xiubao Ren,Bin Meng,Feng Zhang,Yegang Ma,Lin Zhang,Hecheng Li,Xiaozheng Kang,Yin Li,Hongjing Jiang +20 more
TL;DR: According to the hypothesis, preoperative pembrolizumab combined with chemotherapy will result in a better tumour response and prolong the survival of patients, with acceptable toxicity, according to the first prospectively randomized controlled trial designed to compare pembrology plus chemotherapy and chemoradiotherapy as neoadjuvant therapy for resectable ESCC.
39
332O Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells
Huilai Zhang,Xianhuo Wang,L. Dong,H. Lv,Wei Li,Zheng Song,L. Li,Shiyong Zhou,Lihua Qiu,Zhengzi Qian,Xianming Liu,Lixia Feng,Bin Meng,Kai Fu,Q. Pan-Hammarstrom,Ping Wang +15 more
Abstract: Programmed death-1 (PD-1) /programmed death-ligand 1 (PD-L1) engagement usually leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor cells. However, little is known whether PD-1/PD-L1 could directly activates intracellular oncogenic signaling pathways in tumor cells. The purpose of this study is to investigate whether intracellular AKT/mTOR signaling could be directly activated by PD-1/PD-L1 during the malignant progression in diffuse large B-cell lymphoma (DLBCL). Detection of the expression of PD-L1 and p-AKT by immunohistochemistry (IHC) showed that both proteins were overexpressed in 54% and 48% DLBCL cases, respectively. Spearman test showed that PD-L1 expression was correlated with p-AKT expression (R=0.244, χ2=5.962; P=0.017) and the expression of PD-L1 and p-AKT were also correlated with clinic-pathological characteristics. In addition, survival analysis showed that DLBCL patients who co-expressed PD-L1 and p-AKT had significantly poorer outcome than patients with single positive or both negative expression (P<0.05). In vitro, total PD-L1 and membrane PD-L1 (mPD-L1) proteins were overexpressed in five DLBCL cell lines by western blot and flow cytometry. We observed that AKT/mTOR pathway was activated in DLBCL cells after stimulated with human recombination PD-1/Fc. Taken together, these results suggested that the combination of PD-1/PD-L1 antibodies and AKT/mTOR inhibitor might be a promising and novel therapeutic approach for DLBCL in the future.
38